AI assistant
CSL Ltd. — Board/Management Information 2021
Jan 26, 2021
17854_rns_2021-01-26_f34dd5b3-a221-4c4c-84db-679032ae6f2f.pdf
Board/Management Information
Open in viewerOpens in your device viewer
For immediate release
27 January 2021
==> picture [205 x 32] intentionally omitted <==
==> picture [58 x 30] intentionally omitted <==
==> picture [262 x 27] intentionally omitted <==
Resignation of Director
CSL Limited (ASX:CSL; USOTC:CSLLY) advises that the CSL Board of Directors has regretfully, but with mutual agreement, accepted Mr. Pascal Soriot’s resignation from his position of Non-Executive Director, effective 1 February 2021.
Mr Soriot’s departure from the Board was mutually agreed with Mr Soriot, Chief Executive Officer of AstraZeneca PLC. He has resigned to avoid any potential future conflict of strategic interest between CSL and AstraZeneca that may arise due to the acquisition of Alexion by AstraZeneca. The acquisition, announced on 12 December 2020, is subject to a number of closing conditions that have not yet been satisfied.
CSL’s Chair, Dr Brian McNamee AO said “Whilst Pascal has only served for a short time as a Non-Executive Director of CSL, he made a strong contribution and become a valued member of the Board. CSL is regretful that Pascal’s tenure has come to an early close. We look forward to maintaining our ongoing relationship as CSL continues to work closely with AstraZeneca on the critically important COVID-19 vaccine project for the benefit of Australians. On behalf of the CSL Board I thank Pascal for all his work and for his continued relationship with CSL through the vaccine efforts”.
FURTHER INFORMATION
For further information, please contact:
Investors: Mark Dehring Head of Investor Relations CSL Limited Telephone: +613 9389 3407 Email: [email protected]
Media: Christina Hickie Senior Manager, Communications CSL Limited +61 429 609 762 Email: [email protected]
- ® Trademarks of CSL Limited or its affiliates.
==> picture [99 x 7] intentionally omitted <==